Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPd Maintenance in High-Risk Myeloma
NCT05208307Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Jul 2022
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Emory University. Started Jul 2022; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05208307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208307.